

Research Article

AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors

Sharon M. Landers¹, Angela D. Bhalla¹, XiaoYan Ma¹, Kristelle Lusby², Davis Ingram³, Ghadah Al Sannaa⁴, Wei-Lien Wang³, Alexander J. Lazar³, Keila E. Torres^{1*}

¹Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

²Department of Surgery, Division of Plastic Surgery, Indianapolis University School of Medicine, Indianapolis, IN, USA


³Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

⁴Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston TX, USA

***Corresponding Author:** Dr. Keila E. Torres, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Tel: (713) 792-4242; E-mail: ketorres@mdanderson.org

Received: 12 May 2020; **Accepted:** 04 June 2020; **Published:** 15 June 2020

Citation: Sharon M. Landers, Angela D. Bhalla, XiaoYan Ma, Kristelle Lusby, Davis Ingram, Ghadah Al Sannaa, Wei-Lien Wang, Alexander J. Lazar, Keila E. Torres. AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors. Journal of Cancer Science and Clinical Therapeutics 4 (2020): 189-203.



Supplemental Figure 1: AXL knockdown enhances MPNST sensitivity to MEK1/2 inhibition *in vivo*. AXL knockdown enhances the effects of the MEK inhibitor PD0325901 on the growth of MPNST724- NT xenografts (A) and MPNST724-AXLsh1 xenografts (B). (C) IHC analysis of AXL, pAXL, pMEK1/2, pERK, Ki67, and cleaved caspase 3 (CC3) expression in MPNST724 xenografts treated with vehicle or PD0325901. (D) Quantification of Ki-67 IHC staining.



This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC-BY\) license 4.0](https://creativecommons.org/licenses/by/4.0/)